Literature DB >> 791321

Pharmacokinetics of N-demethyldiazepam in patients suffering from insomnia and treated with nortriptyline.

G Tognoni, R Gomeni, D De Maio, G G Alberti, P Franciosi, G Scieghi.   

Abstract

1 Hospitalized patients suffering from insomnia were treated with N-demethyldiazepam (30 mg p.o.) for 10 days, while continuing treatment with nortriptyline (75 or 100 mg daily). 2 Clinical evaluation performed by objective rating scales showed a positive therapeutic effect. No correlation was found however between drug plasma levels and clinical efficacy. A high inter-individual variability was observed. 3 In three cases the N-demethyldiazepam disappearance curve showed a biexponential decay, with a slow first component followed by a faster one. 4 Compared with diazepam the tested drug has a longer plasma apparent half-life and a lower relative clearance.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 791321      PMCID: PMC1402583          DOI: 10.1111/j.1365-2125.1975.tb01580.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  The residual effects of N-desmethyldiazepam in patients.

Authors:  M Tansella; C Zimmermann-Tansella; M Lader
Journal:  Psychopharmacologia       Date:  1974

2.  The concentrations of diazepam and its metabolites in the plasma after an acute and chronic administration.

Authors:  J Kanto; E Iisalo; V Lehtinen; J Salminen
Journal:  Psychopharmacologia       Date:  1974-04-08

3.  Rate of accumulation and plateau plasma concentration of drugs after chronic medication.

Authors:  J M van Rossum; A H Tomey
Journal:  J Pharm Pharmacol       Date:  1968-05       Impact factor: 3.765

4.  The use of N-demethyldiazepam in outpatients suffering from insomnia.

Authors:  G C Tosi; E C Tosi; J R Hattab
Journal:  Curr Ther Res Clin Exp       Date:  1973-07

5.  Plasma concentrations of diazepam and of its metabolite N-desmethyldiazepam in relation to anxiolytic effect.

Authors:  H H Dasberg; E van der Kleijn; J P Guelen; H M van Praag
Journal:  Clin Pharmacol Ther       Date:  1974-05       Impact factor: 6.875

6.  Diazepam metabolism during chronic medication unbound fraction in plasma, erythrocytes and urine.

Authors:  I A Zingales
Journal:  J Chromatogr       Date:  1973-01-03

7.  Pharmacokinetic profile of diazepam in man following single intravenous and oral and chronic oral administrations.

Authors:  S A Kaplan; M L Jack; K Alexander; R E Weinfeld
Journal:  J Pharm Sci       Date:  1973-11       Impact factor: 3.534

8.  Pharmacokinetics of diazepam in dogs, mice and humans.

Authors:  E van der Klejin; J M van Rossum; E T Muskens; N V Rijntjes
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1971

9.  Blood levels of drug at the equilibrium state after multiple dosing.

Authors:  J G Wagner; J I Northam; C D Alway; O S Carpenter
Journal:  Nature       Date:  1965-09-18       Impact factor: 49.962

10.  Diazepam elimination in premature and full term infants, and children.

Authors:  P L Morselli; N Principi; G Tognoni; E Reali; G Belvedere; S M Standen; F Sereni
Journal:  J Perinat Med       Date:  1973       Impact factor: 1.901

View more
  16 in total

1.  Effect of diazepam and fosazepam (a soluble derivative of diazepam) on sleep in man.

Authors:  A N Nicholson; B M Stone; C H Clarke
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

2.  Drug kinetics and artificial kidneys.

Authors:  T B Gibson; H A Nelson
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

3.  Effect of a metabolite of diazepam, 3-hydroxydiazepam (temazepam), on sleep in man.

Authors:  A N Nicholson; B M Stone
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

4.  Effect of N-desmethyldiazepam (nordiazepam) and a precursor, potassium clorazepate, on sleep in man.

Authors:  A N Nicholson; B M Stone; C H Clarke; H M Ferres
Journal:  Br J Clin Pharmacol       Date:  1976-06       Impact factor: 4.335

5.  Pharmacokinetics of prazepam in man.

Authors:  M T Smith; L E Evans; M J Eadie; J H Tyrer
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

6.  Pharmacokinetic aspects of the interaction between clobazam and cimetidine.

Authors:  H G Grigoleit; P Hajdú; H K Hundt; D Koeppen; V Malerczyk; B H Meyer; F O Müller; P U Witte
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Human pharmacokinetics and bioavailability of temazepam administered in soft gelatin capsules.

Authors:  L M Fuccella; G Bolcioni; V Tamassia; L Ferrario; G Tognoni
Journal:  Eur J Clin Pharmacol       Date:  1977-12-16       Impact factor: 2.953

8.  Plasma concentrations of benzodiazepines.

Authors:  A J Bond; D M Hailey; M H Lader
Journal:  Br J Clin Pharmacol       Date:  1977-02       Impact factor: 4.335

Review 9.  Clinical pharmacokinetics of diazepam.

Authors:  M Mandelli; G Tognoni; S Garattini
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

Review 10.  [Clinical pharmacokinetics of diazepam and its biologically active metabolites (author's transl)].

Authors:  U Klotz
Journal:  Klin Wochenschr       Date:  1978-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.